WHAT IS CLAIMED IS:

1. A method for producing Dupilumab, comprising:

   (a) culturing cells expressing Dupilumab using a cell culture medium comprising ornithine at between about 0.09 and about 0.9 mM and/or putrescine at between about 0.20 mM and about 0.9 mM,

   (b) harvesting said cells by centrifugation to separate cell debris from clarified media comprising Dupilumab;

   (c) subjecting said clarified media to affinity chromatography;

   (d) subjecting said Dupilumab pooled from eluate of step (c) to viral inactivation at a pH from about 3 to about 4 and then adjusting the pH to from about 5 to about 8;

   (e) subjecting said Dupilumab pooled from step (d) to anion exchange chromatography in flowthrough mode;

   (f) subjecting said Dupilumab pooled from flowthrough fractions of step (e) to cation exchange chromatography in bind and elute mode;

   (g) subjecting said Dupilumab pooled from eluate of step (f) to hydrophobic interaction chromatography in flowthrough mode;

   (h) subjecting said Dupilumab pooled from flowthrough fractions of step (g) to virus retentive filtration to produce Dupilumab; and

   (i) collecting said Dupilumab.

2. The method of claim 1, wherein said cell culture medium comprises one or more fatty acids.

3. The method of claim 2, wherein said one or more fatty acids are selected from the group consisting of linoleic acid, linolenic acid, thioctic acid, oleic acid, palmitic acid, stearic acid, arachidic acid, arachidonic acid, lauric acid, behenic acid, decanoic acid, dodecanoic acid, hexanoic acid, lignoceric acid, myristic acid, octanoic acid, and combinations thereof.

4. The method of claim 1, wherein said culture medium comprises nucleosides selected from the group consisting of adenosine, guanosine, cytidine, uridine, thymidine, hypoxanthine, and combinations thereof.

5. The method of claim 1, wherein said culture medium comprises amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine,

glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and combinations thereof.

6. The method of claim 1, further comprising the step of adding one or more point-of-use additions to the cell culture medium.
7. A method of producing Dupilumab, comprising the steps of:
   (a) culturing cells expressing Dupilumab using a cell culture medium comprising ornithine at between about 0.09 and about 0.9 mM and/or putrescine at between about 0.20 mM and about 0.9 mM,
   (b) harvesting said cells by centrifugation to separate cell debris from clarified media comprising Dupilumab;
   (c) subjecting said clarified media to affinity chromatography;
   (d) subjecting said Dupilumab pooled from eluate of step (c) to viral inactivation at a pH from about 3 to about 4 and then adjusting the pH to from about 5 to about 8;
   (e) subjecting said Dupilumab pooled from step (d) to cation exchange chromatography in bind and elute mode;
   (f) subjecting said Dupilumab pooled from eluate of step (e) to anion exchange chromatography in flowthrough mode; and
   (g) subjecting said Dupilumab pooled from flowthrough fractions of step (f) to virus retentive filtration to produce Dupilumab.
8. The method of claim 7, wherein said cell culture medium comprises one or more fatty acids selected from the group consisting of linoleic acid, linolenic acid, thioctic acid, oleic acid, palmitic acid, stearic acid, arachidic acid, arachidonic acid, lauric acid, behenic acid, decanoic acid, dodecanoic acid, hexanoic acid, lignoceric acid, myristic acid, octanoic acid, and combinations thereof.
9. The method of claim 7, wherein said culture medium comprises nucleosides selected from the group consisting of adenosine, guanosine, cytidine, uridine, thymidine, hypoxanthine, and combinations thereof.
10. The method of claim 7, wherein said culture medium comprises insulin.
11. The method of claim 7, wherein said culture medium comprises amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine,

glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and combinations thereof.

12. The method of claim 7, further comprising the step of adding one or more point-of-use additions to the cell culture medium.
13. The method of claim 12, wherein said point-of-use additions comprise one or more of NaHCO3, Na2HPO4, taurine, glutamine, poloxamer 188, insulin, glucose, CuSO4, ZnSO4, FeCl3, NiSO4, Na4 EDTA, and Na3 citrate EDTA.
14. The method of claim 7, wherein the culture medium is hydrolysate-free.
15. A method, comprising:

(a) culturing cells expressing anti-IL-4Rα antibody or antigen-binding fragment thereof using a cell culture medium comprising ornithine at between about 0.09 and about 0.9 mM and/or putrescine at between about 0.20 mM and about 0.9 mM,

(b) harvesting said cells by centrifugation to separate cell debris from clarified media comprising the anti-IL-4Rα antibody or antigen binding fragment thereof;

(c) subjecting said clarified media to affinity chromatography;

(d) subjecting said antibody pooled from eluate of step (c) to viral inactivation at a pH from about 3 to about 4 and then adjusting the pH to from about 5 to about 8;

(e) subjecting said anti-IL-4Rα antibody or antigen-binding fragment thereof pooled from step (d) to anion exchange chromatography in flowthrough mode;

(f) subjecting said anti-IL-4Rα antibody or antigen-binding fragment thereof pooled from flowthrough fractions of step (e) to cation exchange chromatography in bind and elute mode;

(g) subjecting said anti-IL-4Rα antibody or antigen-binding fragment thereof pooled from eluate of step (f) to hydrophobic interaction chromatography in flowthrough mode;

(h) subjecting said anti-IL-4Rα antibody or antigen-binding fragment thereof pooled from flowthrough fractions of step (g) to virus retentive filtration to produce an anti-IL4Rα antibody or antigen-binding fragment thereof; and

(i) collecting said anti-IL-4Rα antibody or antigen-binding fragment thereof.

16. The method of claim 15, wherein said cell culture medium comprises one or more fatty acids.
17. The method of claim 16, wherein said one or more fatty acids are selected from the group consisting of linoleic acid, linolenic acid, thioctic acid, oleic acid, palmitic acid, stearic acid, arachidic acid, arachidonic acid, lauric acid, behenic acid, decanoic acid, dodecanoic acid, hexanoic acid, lignoceric acid, myristic acid, octanoic acid, and combinations thereof.
18. The method of claim 15, wherein said culture medium comprises nucleosides selected from the group consisting of adenosine, guanosine, cytidine, uridine, thymidine, hypoxanthine, and combinations thereof.
19. The method of claim 15, wherein said culture medium comprises amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and combinations thereof.
20. The method of claim 15, further comprising the step of adding one or more point-of-use additions to the cell culture medium.
21. The method of claim 20, wherein said point-of-use additions comprise one or more of NaHCO3, Na2HPO4, taurine, glutamine, poloxamer 188, insulin, glucose, CuSO4, ZnSO4, FeCl3, NiSO4, Na4 EDTA, and Na3 citrate EDTA.
22. The method of claim 15, wherein the culture medium is hydrolysate-free.